

Marc Carrier

List of Publications by Citations

Source: <https://exaly.com/author-pdf/1579203/marc-carrier-publications-by-citations.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

229
papers

8,821
citations

39
h-index

91
g-index

253
ext. papers

12,174
ext. citations

8
avg, IF

6.32
L-index

#	Paper	IF	Citations
229	COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review. <i>Journal of the American College of Cardiology</i> , 2020 , 75, 2950-2973	15.1	1682
228	Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism. <i>New England Journal of Medicine</i> , 2018 , 378, 615-624	59.2	806
227	Apixaban to Prevent Venous Thromboembolism in Patients with Cancer. <i>New England Journal of Medicine</i> , 2019 , 380, 711-719	59.2	391
226	Prevention, Diagnosis, and Treatment of VTE in Patients With Coronavirus Disease 2019: CHEST Guideline and Expert Panel Report. <i>Chest</i> , 2020 , 158, 1143-1163	5.3	356
225	Systematic review: case-fatality rates of recurrent venous thromboembolism and major bleeding events among patients treated for venous thromboembolism. <i>Annals of Internal Medicine</i> , 2010 , 152, 578-89	8	314
224	Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19. <i>New England Journal of Medicine</i> , 2021 , 385, 777-789	59.2	227
223	Consensus statements on the risk, prevention, and treatment of venous thromboembolism in inflammatory bowel disease: Canadian Association of Gastroenterology. <i>Gastroenterology</i> , 2014 , 146, 835-848.e6	13.3	205
222	Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19. <i>New England Journal of Medicine</i> , 2021 , 385, 790-802	59.2	203
221	Screening for Occult Cancer in Unprovoked Venous Thromboembolism. <i>New England Journal of Medicine</i> , 2015 , 373, 697-704	59.2	189
220	Aspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthroplasty. <i>New England Journal of Medicine</i> , 2018 , 378, 699-707	59.2	189
219	Systematic review: the Trousseau syndrome revisited: should we screen extensively for cancer in patients with venous thromboembolism?. <i>Annals of Internal Medicine</i> , 2008 , 149, 323-33	8	179
218	Perioperative Management of Patients With Atrial Fibrillation Receiving a Direct Oral Anticoagulant. <i>JAMA Internal Medicine</i> , 2019 , 179, 1469-1478	11.5	156
217	Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): A systematic review and meta-analysis. <i>Thrombosis Research</i> , 2019 , 173, 158-163	8.2	149
216	Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research. <i>Thrombosis and Haemostasis</i> , 2020 , 120, 1004-1024	7	147
215	Development of a clinical prediction rule for risk stratification of recurrent venous thromboembolism in patients with cancer-associated venous thromboembolism. <i>Circulation</i> , 2012 , 126, 448-54	16.7	142
214	Guidance for the prevention and treatment of cancer-associated venous thromboembolism. <i>Journal of Thrombosis and Thrombolysis</i> , 2016 , 41, 81-91	5.1	138
213	Efficacy and safety of anticoagulant therapy for the treatment of acute cancer-associated thrombosis: a systematic review and meta-analysis. <i>Thrombosis Research</i> , 2014 , 134, 1214-9	8.2	129

212	Efficacy and safety outcomes of oral anticoagulants and antiplatelet drugs in the secondary prevention of venous thromboembolism: systematic review and network meta-analysis. <i>BMJ, The</i> , 2013 , 347, f5133	5.9	125
211	Perioperative Management of Dabigatran: A Prospective Cohort Study. <i>Circulation</i> , 2015 , 132, 167-73	16.7	115
210	Prothrombin Complex Concentrate for Major Bleeding on Factor Xa Inhibitors: A Prospective Cohort Study. <i>Thrombosis and Haemostasis</i> , 2018 , 118, 842-851	7	114
209	Lack of evidence to support thromboprophylaxis in hospitalized medical patients with cancer. <i>American Journal of Medicine</i> , 2014 , 127, 82-6.e1	2.4	105
208	Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer Study. <i>Thrombosis and Haemostasis</i> , 2018 , 118, 1439-1449	7	98
207	American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. <i>Blood Advances</i> , 2021 , 5, 927-974	7.8	96
206	Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: A randomized trial. <i>Thrombosis Research</i> , 2017 , 151, 89-95	8.2	93
205	Clinical and safety outcomes associated with treatment of acute venous thromboembolism: a systematic review and meta-analysis. <i>JAMA - Journal of the American Medical Association</i> , 2014 , 312, 1122-33	27.4	92
204	Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis. <i>BMJ, The</i> , 2019 , 366, l4363	5.9	83
203	Systematic review and network meta-analysis comparing antithrombotic agents for the prevention of stroke and major bleeding in patients with atrial fibrillation. <i>BMJ Open</i> , 2014 , 4, e004301	3	80
202	Screening for Occult Cancer in Patients With Unprovoked Venous Thromboembolism: A Systematic Review and Meta-analysis of Individual Patient Data. <i>Annals of Internal Medicine</i> , 2017 , 167, 410-417	8	66
201	Self-reported adherence to anticoagulation and its determinants using the Morisky medication adherence scale. <i>Thrombosis Research</i> , 2015 , 136, 727-31	8.2	63
200	The use of direct oral anticoagulants for primary thromboprophylaxis in ambulatory cancer patients: Guidance from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2019 , 17, 1772-1778	15.4	62
199	The impact of oral anticoagulation on time to surgery in patients hospitalized with hip fracture. <i>Thrombosis Research</i> , 2015 , 136, 962-5	8.2	54
198	Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial. <i>BMJ, The</i> , 2021 , 375, n2400	5.9	54
197	Efficacy and safety of weight-adjusted heparin prophylaxis for the prevention of acute venous thromboembolism among obese patients undergoing bariatric surgery: a systematic review and meta-analysis. <i>Thrombosis Research</i> , 2014 , 133, 682-7	8.2	51
196	A meta-analysis of low-molecular-weight heparin to prevent pregnancy loss in women with inherited thrombophilia. <i>Blood</i> , 2016 , 127, 1650-5	2.2	48
195	Direct oral anticoagulants for cancer-associated venous thromboembolism: a systematic review and meta-analysis. <i>Blood</i> , 2020 , 136, 1433-1441	2.2	45

194	The Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE) Study for Patients on a Direct Oral Anticoagulant Who Need an Elective Surgery or Procedure: Design and Rationale. <i>Thrombosis and Haemostasis</i> , 2017 , 117, 2415-2424	7	45
193	Accuracy and usefulness of a clinical prediction rule and D-dimer testing in excluding deep vein thrombosis in cancer patients. <i>Thrombosis Research</i> , 2008 , 123, 177-83	8.2	44
192	Incidence and risk factors of symptomatic venous thromboembolism related to implanted ports in cancer patients. <i>Thrombosis Research</i> , 2014 , 133, 30-3	8.2	41
191	Development of a Risk Prediction Score for Occult Cancer in Patients With VTE. <i>Chest</i> , 2017 , 151, 564-573	5.3	40
190	Risk factors predictive of occult cancer detection in patients with unprovoked venous thromboembolism. <i>Blood</i> , 2016 , 127, 2035-7	2.2	39
189	Therapeutic Plasma Exchange in Vaccine-Induced Immune Thrombotic Thrombocytopenia. <i>New England Journal of Medicine</i> , 2021 , 385, 857-859	59.2	39
188	Dose escalation of low molecular weight heparin in patients with recurrent cancer-associated thrombosis. <i>Thrombosis Research</i> , 2014 , 134, 93-5	8.2	38
187	VIDAS D-dimer in combination with clinical pre-test probability to rule out pulmonary embolism. A systematic review of management outcome studies. <i>Thrombosis and Haemostasis</i> , 2009 , 101, 886-92	7	35
186	Outcome of central venous catheter associated upper extremity deep vein thrombosis in cancer patients. <i>Thrombosis Research</i> , 2015 , 135, 298-302	8.2	33
185	Anti-Thrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC): Study design and methodology for an international, adaptive Bayesian randomized controlled trial. <i>Clinical Trials</i> , 2020 , 17, 491-500	2.2	33
184	Direct oral anticoagulant for the prevention of thrombosis in ambulatory patients with cancer: A systematic review and meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2019 , 17, 2141-2151	15.4	31
183	Epidemiology, diagnosis, prevention and treatment of catheter-related thrombosis in children and adults. <i>Thrombosis Research</i> , 2017 , 157, 64-71	8.2	30
182	Use of direct oral anticoagulants in patients with thrombotic antiphospholipid syndrome: Guidance from the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. <i>Journal of Thrombosis and Haemostasis</i> , 2020 , 18, 2126-2137	15.4	30
181	Management of anticoagulation for cancer-associated thrombosis in patients with thrombocytopenia: A systematic review. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2018 , 2, 664-669	5.1	30
180	Comprehensive mitigation framework for concurrent application of multiple clinical practice guidelines. <i>Journal of Biomedical Informatics</i> , 2017 , 66, 52-71	10.2	28
179	Symptomatic subsegmental pulmonary embolism: to treat or not to treat?. <i>Hematology American Society of Hematology Education Program</i> , 2017 , 2017, 237-241	3.1	28
178	Incidental venous thromboembolism: is anticoagulation indicated?. <i>Hematology American Society of Hematology Education Program</i> , 2017 , 2017, 121-127	3.1	28
177	How I treat cancer-associated venous thromboembolism. <i>Blood</i> , 2019 , 133, 291-298	2.2	28

176	Anticoagulation of cancer patients with non-valvular atrial fibrillation receiving chemotherapy: Guidance from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2019 , 17, 1247-1252	15.4	27
175	Predicting the risk of recurrent venous thromboembolism in patients with cancer: A prospective cohort study. <i>Thrombosis Research</i> , 2018 , 163, 41-46	8.2	27
174	The prevalence of antibodies to the platelet factor 4-heparin complex and association with access thrombosis in patients on chronic hemodialysis. <i>Thrombosis Research</i> , 2007 , 120, 215-20	8.2	27
173	Risk of venous thromboembolism in pregnant women with essential thrombocythemia: a systematic review and meta-analysis. <i>Blood</i> , 2017 , 129, 934-939	2.2	23
172	Cancer, atrial fibrillation, and stroke. <i>Thrombosis Research</i> , 2017 , 155, 101-105	8.2	23
171	Extended treatment with edoxaban in cancer patients with venous thromboembolism: A post-hoc analysis of the Hokusai-VTE Cancer study. <i>Journal of Thrombosis and Haemostasis</i> , 2019 , 17, 1866-1874	15.4	23
170	Cost effectiveness of the addition of a comprehensive CT scan to the abdomen and pelvis for the detection of cancer after unprovoked venous thromboembolism. <i>Thrombosis Research</i> , 2017 , 151, 67-71	8.2	22
169	Perioperative interruption of direct oral anticoagulants in patients with atrial fibrillation: A systematic review and meta-analysis. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2018 , 2, 282-290	5.1	22
168	Prophylactic and therapeutic anticoagulation for thrombosis: major issues in oncology. <i>Nature Clinical Practice Oncology</i> , 2009 , 6, 74-84		22
167	A systematic review of clinical practice guidelines on the use of low molecular weight heparin and fondaparinux for the treatment and prevention of venous thromboembolism: Implications for research and policy decision-making. <i>PLoS ONE</i> , 2018 , 13, e0207410	3.7	22
166	Apixaban for the prevention of venous thromboembolism in high-risk ambulatory cancer patients receiving chemotherapy: Rational and design of the AVERT trial. <i>Thrombosis Research</i> , 2018 , 164 Suppl 1, S124-S129	8.2	21
165	Risk of Venous Thromboembolism After Hospital Discharge in Patients With Inflammatory Bowel Disease: A Population-based Study. <i>Inflammatory Bowel Diseases</i> , 2020 , 26, 1761-1768	4.5	20
164	Bleeding risk in patients with unprovoked venous thromboembolism: A critical appraisal of clinical prediction scores. <i>Thrombosis Research</i> , 2017 , 152, 52-60	8.2	19
163	A clinical predictive model for post-hospitalisation venous thromboembolism in patients with inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2019 , 49, 1493-1501	6.1	19
162	Extended thromboprophylaxis with low-molecular weight heparin (LMWH) following abdominopelvic cancer surgery. <i>American Journal of Surgery</i> , 2019 , 218, 537-550	2.7	19
161	Management of venous thromboembolism in patients with glioma. <i>Thrombosis Research</i> , 2017 , 156, 105-108	8.08	18
160	Current guidelines do not sufficiently discriminate venous thromboembolism risk in urology. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017 , 35, 457.e1-457.e8	2.8	17
159	Outcomes in a nurse-led peripherally inserted central catheter program: a retrospective cohort study. <i>CMAJ Open</i> , 2017 , 5, E535-E539	2.5	17

158	The use of extended perioperative low molecular weight heparin (tinzaparin) to improve disease-free survival following surgical resection of colon cancer: a pilot randomized controlled trial. <i>Blood Coagulation and Fibrinolysis</i> , 2011 , 22, 760-2	1	17
157	Excluding pulmonary embolism at the bedside with low pre-test probability and D-dimer: safety and clinical utility of 4 methods to assign pre-test probability. <i>Thrombosis Research</i> , 2006 , 117, 469-74	8.2	17
156	Residual pulmonary embolism as a predictor for recurrence after a first unprovoked episode: Results from the REVERSE cohort study. <i>Thrombosis Research</i> , 2018 , 162, 104-109	8.2	17
155	Treatment of Superficial Vein Thrombosis: A Systematic Review and Meta-Analysis. <i>Thrombosis and Haemostasis</i> , 2019 , 119, 479-489	7	16
154	Risk of Hospitalization With Hemorrhage Among Older Adults Taking Clarithromycin vs Azithromycin and Direct Oral Anticoagulants. <i>JAMA Internal Medicine</i> , 2020 , 180, 1052-1060	11.5	16
153	Clinical implications of incidental venous thromboembolism in cancer patients. <i>European Respiratory Journal</i> , 2020 , 55,	13.6	16
152	Extended treatment of venous thromboembolism: a systematic review and network meta-analysis. <i>Heart</i> , 2019 , 105, 545-552	5.1	16
151	The use of anticoagulants for the treatment and prevention of venous thromboembolism in obese patients: implications for safety. <i>Expert Opinion on Drug Safety</i> , 2016 , 15, 65-74	4.1	15
150	Controversies in the management of cancer-associated thrombosis. <i>Expert Review of Hematology</i> , 2017 , 10, 15-22	2.8	15
149	Treatment of cancer-associated thrombosis: perspectives on the use of novel oral anticoagulants. <i>Thrombosis Research</i> , 2014 , 133 Suppl 2, S167-71	8.2	14
148	Hyperacute multi-organ thromboembolic storm in COVID-19: a case report. <i>Journal of Thrombosis and Thrombolysis</i> , 2021 , 51, 25-28	5.1	14
147	The prevention and management of asparaginase-related venous thromboembolism in adults: Guidance from the SSC on Hemostasis and Malignancy of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2020 , 18, 278-284	15.4	13
146	Using Semantic Components to Represent Dynamics of an Interdisciplinary Healthcare Team in a Multi-Agent Decision Support System. <i>Journal of Medical Systems</i> , 2016 , 40, 42	5.1	12
145	The efficacy and safety of anticoagulation in cerebral vein thrombosis: A systematic review and meta-analysis. <i>Thrombosis Research</i> , 2018 , 169, 135-139	8.2	12
144	Long-term risk of postthrombotic syndrome after symptomatic distal deep vein thrombosis: The CACTUS-PTS study. <i>Journal of Thrombosis and Haemostasis</i> , 2020 , 18, 857-864	15.4	12
143	Management of hemostatic complications in acute leukemia: Guidance from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2020 , 18, 3174-3183	15.4	12
142	Coagulopathy of hospitalised COVID-19: A Pragmatic Randomised Controlled Trial of Therapeutic Anticoagulation versus Standard Care as a Rapid Response to the COVID-19 Pandemic (RAPID COVID COAG - RAPID Trial): A structured summary of a study protocol for a randomised controlled trial. <i>Trials</i> , 2021 , 22, 202	2.8	12
141	Effect of occult cancer screening on mortality in patients with unprovoked venous thromboembolism. <i>Thrombosis Research</i> , 2018 , 171, 92-96	8.2	12

140	Periprocedural interruption of anticoagulation in patients with cancer-associated venous thromboembolism: An analysis of thrombotic and bleeding outcomes. <i>Journal of Thrombosis and Haemostasis</i> , 2019 , 17, 1171-1178	15.4	11
139	Low-molecular-weight-heparin versus a coumarin for the prevention of recurrent venous thromboembolism in high- and low-risk patients with active cancer: a post hoc analysis of the CLOT Study. <i>Journal of Thrombosis and Thrombolysis</i> , 2019 , 47, 495-504	5.1	11
138	Risk of major bleeding in patients receiving vitamin K antagonists or low doses of aspirin. A systematic review and meta-analysis. <i>Thrombosis Research</i> , 2016 , 138, 1-6	8.2	11
137	Risk Scores for Occult Cancer in Patients with Venous Thromboembolism: A Post Hoc Analysis of the Hokusai-VTE Study. <i>Thrombosis and Haemostasis</i> , 2018 , 118, 1270-1278	7	11
136	Venous thromboembolism and occult cancer: impact on clinical practice. <i>Thrombosis Research</i> , 2016 , 140 Suppl 1, S8-11	8.2	11
135	Ideating Mobile Health Behavioral Support for Compliance to Therapy for Patients with Chronic Disease: A Case Study of Atrial Fibrillation Management. <i>Journal of Medical Systems</i> , 2018 , 42, 234	5.1	11
134	Cost-effectiveness analysis of low-dose direct oral anticoagulant (DOAC) for the prevention of cancer-associated thrombosis in the United States. <i>Cancer</i> , 2020 , 126, 1736-1748	6.4	11
133	Screening for cancer in patients with unprovoked venous thromboembolism: protocol for a systematic review and individual patient data meta-analysis. <i>BMJ Open</i> , 2017 , 7, e015562	3	10
132	Diagnostic accuracy of three ultrasonography strategies for deep vein thrombosis of the lower extremity: A systematic review and meta-analysis. <i>PLoS ONE</i> , 2020 , 15, e0228788	3.7	10
131	How I treat obese patients with oral anticoagulants. <i>Blood</i> , 2020 , 135, 904-911	2.2	10
130	Randomized trials of therapeutic heparin for COVID-19: A meta-analysis.. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021 , 5, e12638	5.1	10
129	Prevention of venous thromboembolism in ambulatory patients with cancer. <i>ESMO Open</i> , 2020 , 5, e000948	9	9
128	Effect of Antiplatelet Therapy on Survival and Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial.. <i>JAMA - Journal of the American Medical Association</i> , 2022 ,	27.4	9
127	The Efficacy and Safety of Low Molecular Weight Heparin Administration to Improve Survival of Cancer Patients: A Systematic Review and Meta-Analysis. <i>Thrombosis and Haemostasis</i> , 2020 , 120, 832-846	7	8
126	SPECT V/Q for the diagnosis of pulmonary embolism: protocol for a systematic review and meta-analysis of diagnostic accuracy and clinical outcome. <i>BMJ Open</i> , 2018 , 8, e022024	3	8
125	Revisiting occult cancer screening in patients with unprovoked venous thromboembolism. <i>Thrombosis Research</i> , 2018 , 164 Suppl 1, S7-S11	8.2	8
124	A new prognostic strategy for adult patients with acute pulmonary embolism eligible for outpatient therapy. <i>Journal of Thrombosis and Thrombolysis</i> , 2017 , 43, 326-332	5.1	8
123	Development and implementation of common data elements for venous thromboembolism research: on behalf of SSC Subcommittee on official Communication from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2021 , 19, 297-303	15.4	8

122	Effect of oral anticoagulant use on surgical delay and mortality in hip fracture. <i>Bone and Joint Journal</i> , 2021 , 103-B, 222-233	5.6	8
121	Thromboembolic disease in palliative and end-of-life care: A narrative review. <i>Thrombosis Research</i> , 2019 , 175, 84-89	8.2	7
120	Anticoagulation for Subsegmental Pulmonary Embolism. <i>New England Journal of Medicine</i> , 2019 , 381, 1171-1174	59.2	7
119	Management of pregnancy associated venous-thromboembolism: a survey of practices. <i>Thrombosis Journal</i> , 2014 , 12, 12	5.6	7
118	Risk for Recurrent Venous Thromboembolism in Patients With Subsegmental Pulmonary Embolism Managed Without Anticoagulation : A Multicenter Prospective Cohort Study. <i>Annals of Internal Medicine</i> , 2021 ,	8	7
117	Accuracy of the Ottawa score in risk stratification of recurrent venous thromboembolism in patients with cancer-associated venous thromboembolism: a systematic review and meta-analysis. <i>Haematologica</i> , 2020 , 105, 1436-1442	6.6	7
116	Discordant reporting of VTE in pancreatic cancer: A systematic review and meta-analysis of thromboprophylaxis versus chemotherapeutic trials. <i>Journal of Thrombosis and Haemostasis</i> , 2021 , 19, 489-501	15.4	7
115	Management of Cancer-Associated Thrombosis: Unmet Needs and Future Perspectives. <i>TH Open</i> , 2021 , 5, e376-e386	2.7	7
114	Occult cancer detection in venous thromboembolism: the past, the present, and the future. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2017 , 1, 9-13	5.1	6
113	Implanted vascular access device related deep vein thrombosis in oncology patients: A prospective cohort study. <i>Thrombosis Research</i> , 2019 , 177, 117-121	8.2	6
112	Determining the safety of enoxaparin prophylaxis in critically ill patients with severe renal insufficiency - The PACER pilot study. <i>Thrombosis Research</i> , 2016 , 144, 69-71	8.2	6
111	Venous thromboembolism and transfusion after major abdominopelvic surgery. <i>Surgery</i> , 2019 , 166, 1084-1091	5.6	6
110	Treatment of Venous Thromboembolism in Cancer. Historical Perspective and Evolving Role of the Direct Oral Anticoagulants. <i>Cancer Treatment and Research</i> , 2019 , 179, 103-115	3.5	6
109	Management of suspected and confirmed recurrent venous thrombosis while on anticoagulant therapy. What next?. <i>Thrombosis Research</i> , 2019 , 180, 105-109	8.2	6
108	Should we screen patients with unprovoked venous thromboembolism for occult cancers? A pilot study. <i>Blood Coagulation and Fibrinolysis</i> , 2010 , 21, 709-10	1	6
107	Thromboprophylaxis in Patients with COVID-19. A Brief Update to the CHEST Guideline and Expert Panel Report.. <i>Chest</i> , 2022 ,	5.3	6
106	A systematic review on the efficacy and safety of low molecular weight heparin as an anticancer therapeutic in preclinical animal models. <i>Thrombosis Research</i> , 2020 , 195, 103-113	8.2	6
105	MitPlan: A planning approach to mitigating concurrently applied clinical practice guidelines. <i>Artificial Intelligence in Medicine</i> , 2021 , 112, 102002	7.4	6

104	Thrombotic Complications Associated with Immune Checkpoint Inhibitors. <i>Cancers</i> , 2021 , 13,	6.6	6
103	Long-term risk of recurrence after discontinuing anticoagulants for a first unprovoked venous thromboembolism: protocol for a systematic review and meta-analysis. <i>BMJ Open</i> , 2017 , 7, 16950	3	5
102	Management of direct oral anticoagulant associated bleeding: Results of a multinational survey. <i>Thrombosis Research</i> , 2018 , 163, 19-21	8.2	5
101	Patient-Centered Outcomes in the Management of Anemia: A Scoping Review. <i>Transfusion Medicine Reviews</i> , 2019 , 33, 7-11	7.4	5
100	Safety of Primary Thromboprophylaxis Using Apixaban in Ambulatory Cancer Patients with Intracranial Metastatic Disease or Primary Brain Tumors. <i>Thrombosis and Haemostasis</i> , 2019 , 119, 1886-1887	7.8	5
99	Thromboprophylaxis in cancer patients. <i>Seminars in Thrombosis and Hemostasis</i> , 2014 , 40, 395-400	5.3	5
98	D-Dimer Enhances Risk-Targeted Thromboprophylaxis in Ambulatory Patients with Cancer. <i>Oncologist</i> , 2020 , 25, 1075-1083	5.7	5
97	Risk scores for occult cancer in patients with unprovoked venous thromboembolism: Results from an individual patient data meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2020 , 18, 2622-2628	15.4	5
96	Outcomes among patients with cancer and incidental or symptomatic venous thromboembolism: A systematic review and meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2021 , 19, 2468-2479	15.4	5
95	Characteristics and outcomes of patients on concurrent direct oral anticoagulants and targeted anticancer therapies-TacDOAC registry: Communication from the ISTH SSC Subcommittee on Hemostasis and Malignancy. <i>Journal of Thrombosis and Haemostasis</i> , 2021 , 19, 2068-2081	15.4	5
94	Direct oral anticoagulants and cancer-associated VTE: good for all, or just some?. <i>Blood</i> , 2020 , 136, 669-673	6.7	4
93	An ontology-driven framework to support the dynamic formation of an interdisciplinary healthcare team. <i>International Journal of Medical Informatics</i> , 2020 , 136, 104075	5.3	4
92	A Randomized, Open-Label, Blinded Outcome Assessment Trial Evaluating the Efficacy and Safety of LMWH/Edoxaban Versus Dalteparin for Venous Thromboembolism Associated with Cancer: Hokusai VTE-Cancer Study. <i>Blood</i> , 2017 , 130, LBA-6-LBA-6	2.2	4
91	How to manage patients with symptomatic subsegmental pulmonary embolism?. <i>Polish Archives of Internal Medicine</i> , 2020 , 130, 310-316	1.9	4
90	Screening for Occult Cancer in Patients with Venous Thromboembolism. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	4
89	Heparin - Messias or Verschlimmbesserung?. <i>Journal of Thrombosis and Haemostasis</i> , 2021 , 19, 2373-2382	5.4	4
88	Venous Thromboembolism Prophylaxis in Critically Ill Adults: A Systematic Review and Network Meta-analysis. <i>Chest</i> , 2021 ,	5.3	4
87	Treatment Algorithm in Cancer-Associated Thrombosis: Updated Canadian Expert Consensus.. <i>Current Oncology</i> , 2021 , 28, 5434-5451	2.8	4

86	Should we screen extensively for cancer after unprovoked venous thrombosis?. <i>BMJ, The</i> , 2017 , 356, j1081	5.9	3
85	A survey of thrombosis experts evaluating practices and opinions regarding venous thromboprophylaxis in patients post major abdominal surgery. <i>Thrombosis Journal</i> , 2017 , 15, 2	5.6	3
84	Efficacy and safety of Xa inhibitors for the treatment of cancer-associated venous thromboembolism. <i>Expert Opinion on Drug Safety</i> , 2019 , 18, 313-320	4.1	3
83	Clinical Surveillance vs. Anticoagulation For low-risk patiEnts with isolated SubSegmental Pulmonary Embolism: protocol for a multicentre randomised placebo-controlled non-inferiority trial (SAFE-SSPE). <i>BMJ Open</i> , 2020 , 10, e040151	3	3
82	A single-arm feasibility cohort study of rivaroxaban in antiphospholipid syndrome. <i>Pilot and Feasibility Studies</i> , 2020 , 6, 52	1.9	3
81	Venous thromboembolic events in inflammatory bowel diseases: A review of current evidence and guidance on risk in the post-hospitalization setting. <i>Thrombosis Research</i> , 2020 , 194, 26-32	8.2	3
80	Activated prothrombin complex concentrates for direct oral anticoagulant-associated bleeding or urgent surgery: Hemostatic and thrombotic outcomes. <i>Thrombosis Research</i> , 2020 , 195, 21-28	8.2	3
79	The importance of post thrombotic syndrome as an outcome after deep venous thrombosis: A survey of Canadian thrombosis clinicians. <i>Thrombosis Research</i> , 2017 , 159, 13-15	8.2	3
78	Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE) Study: A Perioperative Management Plan for Patients with Atrial Fibrillation Who Are Receiving a Direct Oral Anticoagulant. <i>Blood</i> , 2018 , 132, LBA-5-LBA-5	2.2	3
77	A Prospective Cohort Study of Upper Extremity Deep Vein Thrombosis. <i>Blood</i> , 2015 , 126, 893-893	2.2	3
76	Rivaroxaban Compared to Placebo for the Treatment of Leg Superficial Vein Thrombosis: A Randomized Trial. <i>Seminars in Thrombosis and Hemostasis</i> , 2020 , 46, 977-985	5.3	3
75	Biomarkers in cancer patients at risk for venous thromboembolism: data from the AVERT study. <i>Thrombosis Research</i> , 2020 , 191 Suppl 1, S31-S36	8.2	3
74	Long-term risk of recurrent venous thromboembolism after a first contraceptive-related event: Data from REVERSE cohort study. <i>Journal of Thrombosis and Haemostasis</i> , 2021 , 19, 1526-1532	15.4	3
73	Surgery and the Subtype of Inflammatory Bowel Disease Impact the Risk of Venous Thromboembolism After Hospital Discharge. <i>Digestive Diseases and Sciences</i> , 2021 , 1	4	3
72	Cancer Screening After Unprovoked Venous Thromboembolism: A Teachable Moment. <i>JAMA Internal Medicine</i> , 2016 , 176, 739-40	11.5	3
71	What's new in the prevention and treatment of cancer-associated thrombosis?. <i>Hematology American Society of Hematology Education Program</i> , 2019 , 2019, 158-166	3.1	3
70	Anticoagulant medication adherence for cancer-associated thrombosis: A comparison of LMWH to DOACs. <i>Journal of Thrombosis and Haemostasis</i> , 2021 , 19, 212-220	15.4	3
69	Residual pulmonary vascular obstruction and recurrence after acute pulmonary embolism: protocol for a systematic review and meta-analysis of individual participant data. <i>BMJ Open</i> , 2018 , 8, e023939	3	3

68	Extended Anticoagulant Treatment with Full- or Reduced-Dose Apixaban in Patients with Cancer-Associated Venous Thromboembolism: Rationale and Design of the API-CAT Study. <i>Thrombosis and Haemostasis</i> , 2021 ,	7	3
67	A survey of thrombosis experts evaluating practices and opinions regarding venous thromboprophylaxis in patients with active cancer hospitalized with an acute medical illness. <i>Thrombosis Journal</i> , 2015 , 13, 10	5.6	2
66	Effect of oral anticoagulants on hemostatic and thromboembolic complications in hip fracture: A systematic review and meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2020 , 18, 2566-2581	15.4	2
65	Perioperative interruption of direct oral anticoagulants and vitamin K antagonists in patients with atrial fibrillation: A comparative analysis. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020 , 4, 131-140	5.1	2
64	Defining time in therapeutic range for busy clinicians: frequency of dose changes is a good surrogate marker to identify patients with suboptimal anticoagulation with warfarin. <i>Thrombosis Research</i> , 2014 , 134, 584-6	8.2	2
63	Should we regionalize the management of pulmonary embolism?. <i>Cmaj</i> , 2008 , 178, 58-60	3.5	2
62	Efficacy and safety of primary thromboprophylaxis for the prevention of venous thromboembolism in patients with cancer and a central venous catheter: A systematic review and meta-analysis. <i>Thrombosis Research</i> , 2021 , 208, 58-65	8.2	2
61	Ventilation/perfusion SPECT for the diagnosis of pulmonary embolism: A systematic review. <i>Journal of Thrombosis and Haemostasis</i> , 2020 , 18, 2910-2920	15.4	2
60	Challenging anticoagulation cases: A case of pulmonary embolism shortly after spontaneous brain bleeding. <i>Thrombosis Research</i> , 2021 , 200, 41-47	8.2	2
59	From cellular function to global impact: the vascular perspective on COVID-19. <i>Canadian Journal of Surgery</i> , 2021 , 64, E289-E297	2	2
58	Thromboprophylaxis with rivaroxaban in patients with malignancy and central venous lines (TRIM-Line): A two-center open-label pilot randomized controlled trial. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021 , 5, e12517	5.1	2
57	Safety of using direct oral anticoagulants in the diagnostic workup of outpatients with suspicion of acute venous thromboembolism. <i>Haematologica</i> , 2020 , 105, e307-e309	6.6	2
56	Thromboprophylaxis for patients with newly diagnosed vs. recurrent cancers: a post-hoc analysis of the avert trial. <i>Journal of Thrombosis and Thrombolysis</i> , 2021 , 51, 720-724	5.1	2
55	Safety and efficacy of apixaban thromboprophylaxis in cancer patients with metastatic disease: A post-hoc analysis of the AVERT trial. <i>Thrombosis Research</i> , 2021 , 197, 13-15	8.2	2
54	Recurrent bleeding and thrombotic events after resumption of oral anticoagulants following gastrointestinal bleeding: Communication from the ISTH SSC Subcommittee on Control of Anticoagulation. <i>Journal of Thrombosis and Haemostasis</i> , 2021 , 19, 2618-2628	15.4	2
53	Extended thromboprophylaxis following major abdominal/pelvic cancer-related surgery: A systematic review and meta-analysis of the literature. <i>Thrombosis Research</i> , 2021 , 204, 114-122	8.2	2
52	Risk factors for gastrointestinal bleeding in patients with gastrointestinal cancer using edoxaban. <i>Journal of Thrombosis and Haemostasis</i> , 2021 , 19, 3008-3017	15.4	2
51	The efficacy and safety of anticoagulation in cerebral vein thrombosis: A Systematic review and meta-analysis: Re-Abdulaziz Almulhim, Saad Fallatah, Ivo Abraham. Comparing incomparable with the wrong analytics: anticoagulation, disability, intracranial hemorrhage, and mortality in acute cerebral vein thrombosis. <i>Thrombosis Research</i> Volume 178, June 2019, Pages 110-111. <i>Thrombosis Research</i> , 2019 , 180, 28	8.2	1

50	Debate: Thromboprophylaxis should be considered in all patients with cancer - Yes. <i>Thrombosis Research</i> , 2020 , 191, 142-144	8.2	1
49	Guiding curriculum development of a national research training program in thrombosis medicine: A needs assessment involving faculty and trainees. <i>Thrombosis Research</i> , 2018 , 162, 79-86	8.2	1
48	Occult cancer detection in patients with hemostatic disorder and venous thromboembolism. <i>Thrombosis Research</i> , 2018 , 163, 242-245	8.2	1
47	Treatment of portal vein thrombosis: an updated narrative review. <i>Minerva Medica</i> , 2021 ,	2.2	1
46	Safety and efficacy of apixaban thromboprophylaxis in ambulatory cancer patients according to renal function: A subgroup analysis of the AVERT trial.. <i>Thrombosis Research</i> , 2022 , 211, 85-87	8.2	1
45	Meta-Analysis of Long-Term Risk of Recurrent Venous Thromboembolism after Stopping Anticoagulation in Men and Women with First Unprovoked Venous Thromboembolism. <i>Blood</i> , 2018 , 132, 2527-2527	2.2	1
44	The Risk of Venous Thromboembolism in Pregnant Women with Essential Thrombocythemia: A Systematic Review and Meta-Analysis. <i>Blood</i> , 2016 , 128, 2595-2595	2.2	1
43	Incidence and Risk Factors of Venous Thromboembolism in Patients with Multiple Myeloma Receiving Immunomodulatory Agents. <i>Blood</i> , 2016 , 128, 2624-2624	2.2	1
42	Thromboprophylaxis practice patterns and beliefs among physicians treating patients with abdominopelvic cancers at a Canadian centre. <i>Canadian Journal of Surgery</i> , 2020 , 63, E562-E568	2	1
41	Amiodarone, Verapamil, or Diltiazem Use With Direct Oral Anticoagulants and the Risk of Hemorrhage in Older Adults.. <i>CJC Open</i> , 2022 , 4, 315-323	2	1
40	Cost-utility analysis of apixaban compared with usual care for primary thromboprophylaxis in ambulatory patients with cancer.. <i>Cmaj</i> , 2021 , 193, E1551-E1560	3.5	1
39	Growth differentiation factor-15 for prediction of bleeding in cancer patients. <i>Journal of Thrombosis and Haemostasis</i> , 2021 , 20, 138	15.4	1
38	Patient-Centred Outcomes in Anaemia and Renal Disease: A Systematic Review. <i>Kidney Diseases (Basel, Switzerland)</i> , 2020 , 6, 74-84	3.3	1
37	Efficacy and safety of apixaban for primary prevention in gastrointestinal cancers: A post-hoc analysis of the AVERT trial. <i>Thrombosis Research</i> , 2021 , 202, 151-154	8.2	1
36	Illustrated State-of-the-Art Capsules of the ISTH 2020 Congress. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021 , 5, e12532	5.1	1
35	A Health eLearning Ontology and Procedural Reasoning Approach for Developing Personalized Courses to Teach Patients about Their Medical Condition and Treatment. <i>International Journal of Environmental Research and Public Health</i> , 2021 , 18,	4.6	1
34	Influence of body mass index on clinical outcomes in venous thromboembolism: Insights from GARFIELD-VTE. <i>Journal of Thrombosis and Haemostasis</i> , 2021 , 19, 3031-3043	15.4	1
33	Just the facts: Management of life-threatening bleeding with oral anticoagulant use in the emergency department. <i>Canadian Journal of Emergency Medicine</i> , 2019 , 21, 460-463	0.6	0

32	Efficacy of primary prevention of venous thromboembolism among subgroups of cancer patients undergoing chemotherapy: A post- hoc analysis of the AVERT trial. <i>Thrombosis Research</i> , 2021 , 208, 79-82	8.2	o
31	Impact of anticoagulation on recurrent thrombosis and bleeding after hematopoietic cell transplantation. <i>American Journal of Hematology</i> , 2021 , 96, 1137-1146	7.1	o
30	Clinical and sociodemographic factors associated with anticoagulant use for cancer associated venous thromboembolism. <i>Journal of Thrombosis and Thrombolysis</i> , 2021 , 52, 214-223	5.1	o
29	Timing of Perioperative Pharmacologic Thromboprophylaxis Initiation and its Effect on Venous Thromboembolism and Bleeding Outcomes: A Systematic Review and Meta-Analysis. <i>Journal of the American College of Surgeons</i> , 2021 , 233, 619-631.e14	4.4	o
28	Persistence of Platelets Activation Prior to Second Doses of Covid-19 Vaccine After Vaccine-Induced Immune Thrombotic Thrombocytopenia.. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2022 , 28, 10760296221086283	3.3	o
27	Efficacy and safety of apixaban for primary prevention of thromboembolism in patients with cancer and a central venous catheter: A subgroup analysis of the AVERT Trial. <i>Thrombosis Research</i> , 2022 , 216, 8-10	8.2	o
26	A survey of the use of empiric novel anticoagulants during investigation of stroke. <i>Canadian Journal of Neurological Sciences</i> , 2015 , 42, 135-7	1	
25	The reply. <i>American Journal of Medicine</i> , 2014 , 127, e13	2.4	
24	The reply. <i>American Journal of Medicine</i> , 2014 , 127, e35	2.4	
23	Unusual venous thrombosis. <i>Cmaj</i> , 2014 , 186, 697-8	3.5	
22	Expanding a First-Order Logic Mitigation Framework to Handle Multimorbid Patient Preferences 2015 , 2015, 895-904	0.7	
21	Efficacy and Safety of Primary Thromboprophylaxis for the Prevention of Venous Thromboembolism in Patients with Cancer and Central Venous Catheter: A Systematic Review and Meta-Analysis. <i>Blood</i> , 2021 , 138, 2139-2139	2.2	
20	A Population Cohort Study to Evaluate the Risk of Ischemic Stroke Among Individuals with a New Diagnosis of Cancer Compared to Matched Cancer-Free Controls: Impact of Prior Stroke History. <i>Blood</i> , 2021 , 138, 175-175	2.2	
19	Treatment of Portal, Mesenteric, and Splenic Vein Thrombosis with Rivaroxaban: A Pilot, Prospective Cohort Study. <i>Blood</i> , 2021 , 138, 671-671	2.2	
18	Efficacy and Safety of Apixaban for Primary Prevention of Thromboembolism in Cancer Patients with a Newly Inserted Central Venous Catheter: A Post-Hoc Analysis of the Avert Trial. <i>Blood</i> , 2021 , 138, 2133-2133	2.2	
17	Impact of Race/Ethnicity on Cancer Associated Thrombosis Among Underserved Patients with Cancer. <i>Blood</i> , 2021 , 138, 176-176	2.2	
16	High Prevalence of Antibodies to the Heparin-Platelet Factor 4 Complex in Hemodialysis Patients.. <i>Blood</i> , 2005 , 106, 4119-4119	2.2	
15	Antibodies to the Platelet Factor 4-Heparin Complex and Mortality in Chronic Hemodialysis Patients.. <i>Blood</i> , 2006 , 108, 274-274	2.2	

14	Thrombotic and Bleeding Outcomes Following Perioperative Interruption of Direct Oral Anticoagulants and Vitamin K Antagonists in Patients with Non-Valvular Atrial Fibrillation - a Comparative Analysis. <i>Blood</i> , 2018 , 132, 1234-1234	2.2
13	Long-Term Risk Factors for Occult Cancer Detection in Patients with Unprovoked Venous Thromboembolism: A Post-Hoc Analysis of the Reverse Study. <i>Blood</i> , 2018 , 132, 1230-1230	2.2
12	Cost-Utility Analysis of Apixaban Compared to Usual Care for the Primary Thromboprophylaxis of Ambulatory Cancer Patients Initiating Chemotherapy. <i>Blood</i> , 2019 , 134, 329-329	2.2
11	Meta-Analysis and Cost-Effectiveness Analysis of Low-Dose Direct Oral Anticoagulant for the Prevention of Cancer Associated Thrombosis. <i>Blood</i> , 2019 , 134, 4669-4669	2.2
10	Risk of Venous Thromboembolism in Hospitalized Patients with Sickle Cell Disease. <i>Blood</i> , 2016 , 128, 4755-4755	2.2
9	Practical Application of the 10 Mg Warfarin Initiation Nomogram. <i>Blood</i> , 2008 , 112, 4054-4054	2.2
8	Perioperative Management Of Patients On Dabigatran  Prospective Cohort Study. <i>Blood</i> , 2013 , 122, 3637-3637	2.2
7	Predictors of long-term cancer diagnosis after an unprovoked thromboembolic event: A post-hoc analysis of the REVERSE cohort study. <i>Thrombosis Research</i> , 2020 , 185, 132-134	8.2
6	Biomarker-enhanced VTE risk stratification in ambulatory patients with cancer. <i>Thrombosis Research</i> , 2020 , 196, 437-443	8.2
5	Antithrombotic regimens in females with symptomatic lower extremity peripheral arterial disease: protocol for a systematic review and meta-analysis. <i>BMJ Open</i> , 2021 , 11, e042980	3
4	Media portrayals of pulmonary embolism. <i>Thrombosis Research</i> , 2021 , 206, 52-54	8.2
3	A Framework for Modeling Workflow Execution by an Interdisciplinary Healthcare Team. <i>Studies in Health Technology and Informatics</i> , 2015 , 216, 1100	0.5
2	Risk for Recurrent Venous Thromboembolism in Patients With Subsegmental Pulmonary Embolism Managed Without Anticoagulation.. <i>Annals of Internal Medicine</i> , 2022 , 175, W43-W44	8
1	Towards a framework for comparing functionalities of multimorbidity clinical decision support: A literature-based feature set and benchmark cases. 2021 , 2021, 920-929	0.7